medigraphic.com
Colegio de Medicina Interna de México.

2015, Number 2

<< Back Next >>

Med Int Mex 2015; 31 (2)

Hypokalemic paralysis as manifestation of Graves’ disease

Del Río-Prado AF, González-López JA, Casillas-Villafaña F

Language: Spanish
References: 14
Page: 217-222
PDF size: 466.37 Kb.


ABSTRACT

Thyrotoxic periodic paralysis is an unusual complication of hyperthyroidism that frequently presents in a dramatic fashion, needing treatment in an emergency department or admission to an intensive care unit. It is characterized by recurrent episodes of flaccid muscle paralysis, hypokalemia and elevated levels of triiodothyronine (T3) and thyroxine (T4). Potassium supplementation and B-adrenergic blockers are essential in the prevention of cardiopulmonary complications, and the effective control of hyperthyroidism is indicated to prevent the recurrence of paralysis.


REFERENCES

  1. Burge J, Hanna M. Novel insights into the pathomechanisms of skeletal muscle channelopathies. Curr Neurol Neurosci Rep 2012;12:62-69.

  2. Patel H, Wilches L, Guerrero J. Thyrotoxic periodic paralysis: Diversity in America. J Emerg Medicine dx.doi. org/10.1016/j.jemermed.2013.08.104.

  3. Kung A. Clinical review: Thyrotoxic periodic paralysis: A diagnostic challenge. J Clin Endocrinol Metab 2006;91:2490-2495.

  4. Chang C, Cheng C, Sung C, Chiueh T, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol 2013;169:529-536.

  5. Maciel R, Lindsey S, Dias da Silva M. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol 2011;7:657-667.

  6. Cheng C, Kuo E, Huang C. Extracellular potassium homeostasis: Insights from hypokalemic periodic paralysis. Semin Nephrol 2013;33:237-247.

  7. Biering H, Bauditz J, Pirlich M, Lochs H, Gerl H. Manifestation of thyrotoxic periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemia. Horm Res 2003;59:301-304.

  8. Falhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine 2013;43:274-284.

  9. Lin S, Huang C. Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol 2012;23:985-988.

  10. Ryan D, Dias da Silva M, Soong T, Fontaine B, et al. Mutations in potassium channel Kir 2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010;140:88-98.

  11. Cheng C, Lin S, Lo Y, Yang S, et al. Identification and functional characterization of Kir 2.6 mutations associated with Non-familial hypokalemic periodic paralysis. J Biol Chem 2011;286:27425-27435.

  12. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: Clinical challenges. J Thyroid Res 2014, ID 649502.

  13. Pothiwala P. Levine S. Analytic review: Thyrotoxic periodic paralysis: A review. J Intensive Care Med 2010;25:71-77.

  14. Barahona M, Vinagre I, Sojo L, Cubero M, Pérez A. Thyrotoxic periodic paralysis: A case report and literature review. Clin Med Res 2009;7:96-98.




2020     |     www.medigraphic.com